human
coronaviru
infect
infant
elderli
peopl
immunocompromis
patient
caus
sever
diseas
thu
call
develop
effect
safe
therapeut
treat
report
design
synthesi
character
two
peptidebas
membran
fusion
inhibitor
target
spike
protein
heptad
repeat
heptad
repeat
domain
respect
found
could
interact
form
stabl
sixhelix
bundl
inhibit
spike
proteinmedi
cellcel
fusion
ic
respect
effect
inhibit
pseudotyp
live
infect
ic
respect
mous
model
administ
intranas
could
wide
distribut
upper
lower
respiratori
tract
maintain
fusioninhibitori
activ
therefor
promis
candid
develop
antivir
agent
treatment
prevent
infect
coronavirus
cov
positivesens
rna
envelop
virus
variou
host
includ
avian
speci
mammal
current
six
cov
report
infect
human
includ
human
coronaviru
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
middl
east
respiratori
syndrom
mer
coronaviru
merscov
epidem
sar
approxim
individu
infect
sarscov
mortal
rate
epidem
mer
laboratoryconfirm
case
includ
relat
death
mortal
rate
countri
report
world
health
organ
infect
human
coronavirus
includ
healthi
adult
gener
result
common
cold
clinic
manifest
includ
discomfort
headach
sneez
fever
cough
howev
infect
virus
infant
elderli
peopl
immunocompromis
patient
may
also
caus
sever
diseas
although
first
isol
molecular
clock
analys
indic
emerg
year
ago
evolutionari
studi
suggest
evolutionari
origin
hipposiderid
bat
camelid
may
serv
intermedi
host
current
continu
evolv
mutat
recombin
lead
chang
spike
immunogen
infect
mechan
even
clinic
symptom
exampl
serolog
studi
report
infect
sendaih
new
isol
possibl
relat
kawasaki
diseas
therefor
essenti
develop
potent
inhibitor
treat
infect
control
potenti
epidem
spread
similar
cov
belong
type
envelop
viru
spike
consist
subunit
viral
membran
play
vital
role
viral
entri
host
cell
subunit
contain
receptorbind
domain
rbd
bind
cellular
receptor
aminopeptidas
n
apn
subunit
compris
fusion
peptid
fp
heptad
repeat
heptad
repeat
transmembran
domain
tm
cytoplasm
domain
fusion
cp
respons
mediat
viral
fusion
entri
nativ
state
protein
inact
precursor
viral
infect
process
target
cell
proteas
activ
protein
cleav
subunit
exampl
enter
host
cell
plasma
membran
fusion
pathway
protein
cleav
activ
transmembran
proteas
serin
human
airway
trypsinlik
proteas
hat
interestingli
express
wide
human
respiratori
tract
epitheli
cell
also
target
viral
infect
therefor
play
import
role
promot
infect
human
airway
howev
infect
target
cell
endosom
membran
fusion
pathway
protein
cleav
activ
cathepsin
l
cpl
phdepend
cystein
proteas
endosom
previous
other
discov
cpeptid
deriv
human
immunodefici
viru
type
region
possess
highli
potent
fusion
inhibitori
activ
among
approv
us
food
drug
administr
fda
first
hiv
fusion
inhibitorbas
antihiv
drug
subsequ
identifi
sever
target
domain
protein
sarscov
merscov
potent
viral
fusion
inhibitori
activ
mechan
action
well
document
shown
figur
rbd
bind
coronaviru
correspond
receptor
chang
conform
includ
insert
fp
target
cell
membran
exposur
prehairpin
coil
coil
domain
interact
viral
domain
trimer
form
sixhelix
bundl
thu
bring
viral
envelop
cell
membran
close
proxim
viral
fusion
entri
prefus
intermedi
state
peptid
deriv
domain
cov
protein
design
interact
viral
expos
domain
respect
competit
inhibit
viral
autolog
format
thu
block
viruscel
membran
fusion
although
fusion
core
character
peptidebas
fusion
inhibitor
ever
report
therefor
design
synthes
peptid
deriv
domain
protein
subunit
test
inhibitori
activ
proteinmedi
cellcel
fusion
pseudotyp
live
infect
present
studi
model
membran
fusion
mediat
coronaviru
cov
spike
protein
mechan
heptad
repeat
peptid
heptad
repeat
peptid
nativ
state
fusion
peptid
fp
heptad
repeat
heptad
repeat
domain
subunit
shield
subunit
receptorbind
state
subunit
bind
receptor
target
cell
surfac
prehairpin
state
subunit
dissoci
fp
subunit
insert
target
cell
membran
result
format
fusion
core
final
fusion
cell
viru
membran
peptid
interact
viral
domain
respect
block
viral
fusion
core
format
inhibit
viral
cellular
membran
fusion
cross
arrow
mean
peptid
block
viral
membran
fusion
process
fusion
core
spike
protein
sever
coronavirus
alreadi
crystal
relat
peptid
fusion
inhibitor
studi
howev
fusion
inhibitor
report
far
therefor
herein
report
design
synthesi
two
peptid
design
span
residu
domain
domain
spike
protein
respect
figur
investig
whether
interact
form
incub
phosphat
buffer
salin
pb
respect
min
load
sampl
trisglycin
gel
follow
analysi
npage
previous
describ
shown
figur
similar
peptid
sarscov
merscov
protein
alon
display
band
gel
lane
peptid
carri
net
posit
charg
thu
move
gel
nativ
electrophoresi
condit
alon
show
band
lower
part
gel
lane
howev
mixtur
respect
show
new
band
correspond
upper
part
gel
lane
confirm
interact
form
studi
characterist
interact
determin
secondari
structur
complex
mixtur
circulardichro
cd
spectroscopi
shown
figur
alon
display
rel
low
structur
wherea
mixtur
equimolar
concentr
show
complex
high
character
saddleshap
neg
peak
nm
far
uv
region
cd
spectrum
meanwhil
helic
bundl
show
strong
thermal
stabil
tm
figur
higher
merscov
complex
figur
model
membran
fusion
mediat
coronaviru
cov
spike
protein
mechan
heptad
repeat
peptid
heptad
repeat
peptid
nativ
state
fusion
peptid
fp
heptad
repeat
heptad
repeat
domain
subunit
shield
subunit
receptorbind
state
subunit
bind
receptor
target
cell
surfac
prehairpin
state
subunit
dissoci
fp
subunit
insert
target
cell
membran
result
format
fusion
core
final
fusion
cell
viru
membran
peptid
interact
viral
domain
respect
block
viral
fusion
core
format
inhibit
viral
cellular
membran
fusion
cross
arrow
mean
peptid
block
viral
membran
fusion
process
fusion
core
spike
protein
sever
coronavirus
alreadi
crystal
relat
peptid
fusion
inhibitor
studi
howev
fusion
inhibitor
report
far
therefor
herein
report
design
synthesi
two
peptid
design
span
residu
domain
domain
spike
protein
respect
figur
investig
whether
interact
form
incub
phosphat
buffer
salin
pb
respect
c
min
load
sampl
trisglycin
gel
follow
analysi
npage
previous
describ
shown
figur
similar
peptid
sarscov
merscov
protein
alon
display
band
gel
lane
peptid
carri
net
posit
charg
thu
move
gel
nativ
electrophoresi
condit
alon
show
band
lower
part
gel
lane
howev
mixtur
respect
show
new
band
correspond
upper
part
gel
lane
confirm
interact
form
studi
characterist
interact
determin
secondari
structur
complex
mixtur
circulardichro
cd
spectroscopi
shown
figur
alon
display
rel
low
structur
wherea
mixtur
equimolar
concentr
show
complex
high
character
saddleshap
neg
peak
nm
far
uv
region
cd
spectrum
meanwhil
helic
bundl
show
strong
thermal
stabil
tm
c
figur
higher
merscov
complex
c
result
confirm
peptid
deriv
domain
capabl
harbor
biolog
activ
requir
mimic
viral
fusion
core
structur
form
vitro
meanwhil
complex
provid
use
model
studi
detail
role
fusion
core
mediat
viral
fusion
entri
result
confirm
peptid
deriv
domain
capabl
harbor
biolog
activ
requir
mimic
viral
fusion
core
structur
form
vitro
meanwhil
complex
provid
use
model
studi
detail
role
fusion
core
mediat
viral
fusion
entri
report
cell
could
form
syncytia
uninfect
cell
presenc
trypsin
suggest
turn
protein
cell
may
mediat
fusion
infect
uninfect
cell
accordingli
assess
inhibitori
activ
establish
cellcel
fusion
model
accomplish
use
cell
natur
express
apn
receptor
cell
surfac
cell
simultan
coexpress
protein
cell
surfac
enhanc
green
fluoresc
protein
egfp
cytoplasm
target
effector
cell
respect
figur
cocultur
effector
cell
target
cell
h
could
observ
cell
appar
fuse
use
fluoresc
microscopi
show
larger
size
weaker
fluoresc
unfus
cell
explain
diffus
fluoresc
one
cell
fuse
togeth
figur
stain
dapi
could
clearli
see
sever
nuclei
one
fuse
cell
howev
cell
cultur
alon
contain
one
singl
nucleu
suggest
effector
cell
spontan
fuse
undergo
propag
divis
influenc
assess
fusion
besid
cell
express
protein
cell
surfac
could
fuse
target
cell
cell
also
contain
one
nucleu
h
obviou
format
syncytium
occur
shown
figur
consist
report
cell
could
form
syncytia
uninfect
cell
presenc
trypsin
suggest
turn
protein
cell
may
mediat
fusion
infect
uninfect
cell
accordingli
assess
inhibitori
activ
establish
cellcel
fusion
model
accomplish
use
cell
natur
express
apn
receptor
cell
surfac
cell
simultan
coexpress
protein
cell
surfac
enhanc
green
fluoresc
protein
egfp
cytoplasm
target
effector
cell
respect
figur
cocultur
effector
cell
target
cell
c
h
could
observ
cell
appar
fuse
use
fluoresc
microscopi
show
larger
size
weaker
fluoresc
unfus
cell
explain
diffus
fluoresc
one
cell
fuse
togeth
figur
stain
dapi
could
clearli
see
sever
nuclei
one
fuse
cell
howev
cell
cultur
alon
contain
one
singl
nucleu
suggest
effector
cell
spontan
fuse
undergo
propag
divis
influenc
assess
fusion
besid
cell
express
protein
cell
surfac
could
fuse
target
cell
cell
also
contain
one
nucleu
h
obviou
format
syncytium
occur
shown
figur
consist
previou
report
trypsin
could
effect
promot
cellcel
fusion
timeand
dosedepend
manner
figur
find
confirm
protein
mediat
membran
fusion
effector
cell
target
cell
follow
syncytium
format
suggest
cellcel
fusion
assay
use
studi
proteinmedi
membran
fusion
process
identifi
fusion
entri
inhibitor
previou
report
trypsin
could
effect
promot
cellcel
fusion
timeand
dosedepend
manner
figur
find
confirm
protein
mediat
membran
fusion
effector
cell
target
cell
follow
syncytium
format
suggest
cellcel
fusion
assay
use
studi
proteinmedi
membran
fusion
process
identifi
fusion
entri
inhibitor
next
use
establish
cellcel
fusion
assay
describ
test
inhibitori
activ
smediat
cellcel
fusion
shown
figur
could
effect
inhibit
smediat
cellcel
fusion
ic
respect
exhibit
signific
inhibit
vesicular
stomat
viru
vsv
g
proteinmedi
cellcel
fusion
concentr
high
togeth
result
suggest
effect
inhibit
smediat
membran
fusion
next
use
establish
cellcel
fusion
assay
describ
test
inhibitori
activ
smediat
cellcel
fusion
shown
figur
could
effect
inhibit
smediat
cellcel
fusion
respect
exhibit
signific
inhibit
vesicular
stomat
viru
vsv
g
proteinmedi
cellcel
fusion
concentr
high
togeth
result
suggest
effect
inhibit
smediat
membran
fusion
use
establish
pseudoviru
infect
assay
test
potenti
inhibitori
activ
pseudoviru
infect
cell
shown
figur
could
significantli
inhibit
pseudoviru
infect
dosedepend
manner
valu
wherea
exhibit
moder
inhibit
result
confirm
effect
inhibit
pseudoviru
infect
consist
previou
studi
report
antivir
activ
peptidebas
sarscov
merscov
fusion
inhibitor
next
use
establish
cytopath
effect
cpe
base
viral
inhibit
assay
determin
antivir
activ
live
infect
replic
cell
found
could
effect
inhibit
infect
replic
cell
dosedepend
manner
use
establish
pseudoviru
infect
assay
test
potenti
inhibitori
activ
pseudoviru
infect
cell
shown
figur
could
significantli
inhibit
pseudoviru
infect
dosedepend
manner
ic
valu
wherea
exhibit
moder
inhibit
ic
result
confirm
effect
inhibit
pseudoviru
infect
consist
previou
studi
report
antivir
activ
peptidebas
sarscov
merscov
fusion
inhibitor
next
use
establish
cytopath
effect
cpe
base
viral
inhibit
assay
determin
antivir
activ
live
infect
replic
cell
found
could
effect
inhibit
infect
replic
cell
dosedepend
manner
ic
valu
respect
figur
consist
inhibitori
activ
cell
human
respiratori
epitheli
cell
line
suscept
infect
replic
figur
test
potenti
cytotox
cell
use
target
cell
assay
cellcel
fusion
pseudotyp
live
infect
neither
signific
cytotox
cell
concentr
figur
select
index
si
suggest
could
develop
effect
safe
fusion
inhibitor
clinic
use
respiratori
tract
key
target
viral
infect
proteolyt
enzym
surfac
respiratori
tract
mucosa
may
caus
degrad
peptid
result
attenu
antivir
activ
therefor
antivir
activ
verifi
respiratori
tract
mice
intranas
administ
without
one
hour
later
upper
lower
respiratori
tract
lavag
fluid
respect
collect
test
inhibitori
activ
proteinmedi
cellcel
fusion
shown
figur
upper
test
potenti
cytotox
cell
use
target
cell
assay
cellcel
fusion
pseudotyp
live
infect
neither
signific
cytotox
cell
concentr
figur
select
index
si
cc
ic
suggest
could
develop
effect
safe
fusion
inhibitor
clinic
use
test
potenti
cytotox
cell
use
target
cell
assay
cellcel
fusion
pseudotyp
live
infect
neither
signific
cytotox
cell
concentr
figur
select
index
si
suggest
could
develop
effect
safe
fusion
inhibitor
clinic
use
respiratori
tract
key
target
viral
infect
proteolyt
enzym
surfac
respiratori
tract
mucosa
may
caus
degrad
peptid
result
attenu
antivir
activ
therefor
antivir
activ
verifi
respiratori
tract
mice
intranas
administ
without
one
hour
later
upper
lower
respiratori
tract
lavag
fluid
respect
collect
test
inhibitori
activ
proteinmedi
cellcel
fusion
shown
figur
upper
respiratori
tract
key
target
viral
infect
proteolyt
enzym
surfac
respiratori
tract
mucosa
may
caus
degrad
peptid
result
attenu
antivir
activ
therefor
antivir
activ
verifi
respiratori
tract
mice
intranas
administ
without
one
hour
later
upper
lower
respiratori
tract
lavag
fluid
respect
collect
test
inhibitori
activ
proteinmedi
cellcel
fusion
shown
figur
upper
lower
respiratori
tract
lavag
fluid
mice
treat
dilut
respect
exhibit
signific
viral
membran
fusioninhibitori
activ
find
suggest
may
degrad
proteolyt
enzym
peptid
maintain
effect
antivir
activ
upper
lower
respiratori
tract
infect
base
previou
experi
discoveri
fusion
inhibitori
peptid
hiv
sarscov
merscov
design
synthes
peptid
deriv
domain
protein
subunit
respect
base
biophys
analys
shown
peptid
interact
form
strong
thermal
stabil
suggest
may
interact
viral
domain
respect
form
heterolog
thu
block
viral
fusion
core
format
inhibit
fusion
viral
target
cell
membran
inde
show
high
potenc
inhibit
smediat
cellcel
fusion
pseudotyp
live
infect
consist
result
peptid
hiv
sarscov
merscov
howev
contrast
peptid
deriv
sarscov
merscov
protein
show
membran
fusion
inhibitori
activ
also
exhibit
inhibitori
infect
albeit
less
potenc
possibl
peptid
protein
higher
either
sarscov
merscov
therefor
may
easier
form
trimer
interact
viral
domain
similarli
peptid
deriv
domain
could
form
trimer
solut
thu
lack
fusion
inhibitori
activ
howev
trimer
motif
foldon
fd
conjug
cterminu
could
form
trimer
solut
exhibit
potent
activ
therefor
antivir
activ
may
improv
ad
fd
cterminu
peptid
similar
coronavirus
enter
target
cell
two
pathway
either
plasma
membran
fusion
endosom
membran
fusion
depend
proteas
present
target
cell
endosom
pathway
cpl
play
import
role
cleav
activ
protein
inhibitor
cpl
could
inhibit
infect
bertram
et
al
report
target
cell
respiratori
epithelium
could
cleav
activ
promot
viral
infect
human
airway
epitheli
cell
express
cell
surfac
associ
sever
coronaviru
receptor
angiotensin
convert
enzym
dipeptidyl
apn
suggest
assist
base
previou
experi
discoveri
fusion
inhibitori
peptid
hiv
sarscov
merscov
design
synthes
peptid
deriv
domain
protein
subunit
respect
base
biophys
analys
shown
peptid
interact
form
strong
thermal
stabil
suggest
may
interact
viral
domain
respect
form
heterolog
thu
block
viral
fusion
core
format
inhibit
fusion
viral
target
cell
membran
inde
show
high
potenc
inhibit
smediat
cellcel
fusion
pseudotyp
live
infect
consist
result
peptid
hiv
sarscov
merscov
howev
contrast
peptid
deriv
sarscov
merscov
protein
show
membran
fusion
inhibitori
activ
also
exhibit
inhibitori
infect
albeit
less
potenc
possibl
peptid
protein
higher
either
sarscov
merscov
therefor
may
easier
form
trimer
interact
viral
domain
similarli
peptid
deriv
domain
could
form
trimer
solut
thu
lack
fusion
inhibitori
activ
howev
trimer
motif
foldon
fd
conjug
cterminu
could
form
trimer
solut
exhibit
potent
activ
therefor
antivir
activ
may
improv
ad
fd
cterminu
peptid
similar
coronavirus
enter
target
cell
two
pathway
either
plasma
membran
fusion
endosom
membran
fusion
depend
proteas
present
target
cell
endosom
pathway
cpl
play
import
role
cleav
activ
protein
inhibitor
cpl
could
inhibit
infect
bertram
et
al
report
target
cell
respiratori
epithelium
could
cleav
activ
promot
viral
infect
human
airway
epitheli
cell
express
cell
surfac
associ
sever
coronaviru
receptor
angiotensin
convert
enzym
dipeptidyl
apn
suggest
assist
mani
coronavirus
infect
human
airway
epitheli
cell
plasma
membran
fusion
rout
recent
matsuyama
et
al
report
current
clinic
isol
prefer
use
rather
cpl
infect
epitheli
cell
human
respiratori
tract
suggest
fusion
inhibitori
peptid
expect
inhibit
membran
fusion
mediat
protein
proteolyt
process
differ
coronavirus
possess
differ
infect
characterist
human
respiratori
tract
exampl
merscov
mainli
infect
human
lower
respiratori
tract
prone
infect
human
upper
respiratori
tract
caus
common
cold
howev
studi
shown
mainli
caus
lower
respiratori
tract
infect
pediatr
case
found
could
retain
activ
upper
lower
respiratori
tract
suggest
use
block
infect
upper
lower
respiratori
tract
intranas
applic
recent
sever
coronaviru
inhibitor
differ
mechan
action
infect
vitro
report
exampl
cinanserin
target
viral
like
proteinas
inhibit
synthesi
membranebound
viral
rna
n
chitosan
chlorid
htcc
polym
inhibit
interact
viru
receptor
phospholipas
pla
inhibitor
silvestrol
eukaryot
initi
factor
inhibitor
chloroquin
inhibit
activ
cellular
mitogenactiv
protein
kinas
mapk
contrast
inhibitor
inhibit
fusion
entri
target
cell
target
respect
therefor
reason
specul
combin
inhibitor
differ
antivir
mechan
may
synergist
effect
infect
previous
demonstr
intranas
applic
combin
exhibit
signific
synergist
activ
summari
design
synthes
two
peptid
fusion
inhibitor
deriv
domain
protein
subunit
peptid
interact
form
highli
stabl
exhibit
potent
inhibitori
activ
proteinmedi
cellcel
fusion
pesudoviru
infect
live
replic
human
respiratori
epitheli
cell
detect
cytotox
meanwhil
abl
maintain
fusioninhibitori
activ
upper
lower
respiratori
tract
suggest
promis
candid
develop
effect
safe
fusion
inhibitor
prevent
treatment
infect
cell
cultur
dulbecco
modifi
eagl
medium
dmem
invitrogen
carlsbad
ca
usa
cell
cultur
media
supplement
fetal
bovin
serum
fb
biowest
loir
valley
franc
antibiot
penicillin
streptomycin
cytogen
wetzlar
germani
cell
maintain
c
co
atmospher
american
type
cultur
collect
atcc
strain
propag
cell
viral
titer
tcid
ml
determin
cell
peptid
synthes
karebay
biochem
ningbo
china
use
standard
solidphas
fmoc
method
peptid
test
highperform
liquid
chromatographi
hplc
puriti
peptid
store
c
solubil
dimethyl
sulfoxid
dmso
pb
concentr
peptid
test
uv
absorb
thermo
fisher
scientif
inc
waltham
usa
molarextinct
coeffici
calcul
base
tryptophan
tyrosin
residu
nativ
polyacrylamid
gel
electrophoresi
npage
perform
previous
describ
trisglycin
gel
tricin
glycin
run
buffer
ph
use
npage
peptid
pb
incub
peptid
respect
c
min
peptid
mix
trisglycin
nativ
sampl
buffer
load
onto
npage
gel
electrophoresi
perform
room
temperatur
approxim
h
use
constant
voltag
v
gel
stain
coomassi
blue
imag
fluorchem
imag
system
alpha
innotechproteinsimpl
san
jose
ca
usa
circular
dichroism
cd
spectroscopi
perform
accord
previous
describ
protocol
briefli
incub
equal
molar
concentr
c
min
final
concentr
peptid
pb
ph
cd
spectra
test
spectropolarimet
model
jasco
inc
easton
md
usa
nm
baselin
curv
determin
pb
alon
ellipt
valu
nm
taken
helix
format
melt
temperatur
tm
experi
conduct
monitor
chang
ellipt
nm
c
c
rate
cmin
similar
merscov
cellcel
fusion
system
previous
describ
clone
spike
gene
paaviresegfp
vector
transfect
recombin
plasmid
cell
transient
express
gfp
protein
cytoplasm
membran
surfac
herein
use
effector
cell
cell
natur
express
receptor
apn
membran
surfac
target
cell
cell
cultur
alon
cocultur
cell
c
h
stain
cell
nucleu
dapi
fuse
unfus
cell
visibl
optic
microscop
fluoresc
nikon
tokyo
japan
cocultur
c
h
syncytium
format
observ
cell
cell
addit
microscopi
cell
cell
coincub
c
min
h
absenc
presenc
trypsin
grade
concentr
number
fuse
unfus
cell
count
calcul
fusion
rate
use
cell
express
egfp
effector
cell
control
effector
cell
produc
cotransfect
plasmid
carri
sequenc
vsvg
protein
paaviresgfp
vector
fuse
cell
condit
describ
elsewher
absenc
presenc
detect
peptid
differ
concentr
cell
coincub
cell
cell
c
h
number
fuse
unfus
cell
count
percentag
inhibit
cellcel
fusion
calcul
accord
previous
describ
method
pseudoviru
carri
protein
construct
pseudoviru
infect
assay
develop
base
experi
establish
merscov
pseudoviru
infect
assay
perform
describ
previous
briefli
pseudoviru
gener
via
cotransfect
cell
proteinexpress
plasmid
kindli
provid
fang
li
backbon
plasmid
cell
supernat
harvest
h
transfect
centrifug
g
c
min
measur
antivir
activ
peptid
peptid
test
prepar
dilut
incub
pseudoviru
h
c
viruspeptid
mixtur
ad
cell
per
well
cultur
refe
fresh
medium
h
postinfect
incub
addit
h
c
luciferas
activ
measur
use
luciferas
assay
reagent
promega
madison
wi
usa
luminesc
counter
infinit
tecan
nc
usa
percent
inhibit
ic
valu
calcul
use
calcusyn
softwar
kindli
provid
tc
chou
cpebas
viral
inhibit
assay
measur
antivir
activ
peptid
live
establish
detect
antizika
viru
activ
briefli
peptid
solut
mix
tcid
incub
c
h
mixtur
ad
cell
seed
plate
follow
incub
c
h
cultur
supernat
replac
fresh
serumfre
dmem
three
eight
day
later
cpe
becam
evid
antivir
activ
detect
use
cell
count
dojindo
kumamoto
kyushu
japan
accord
instruct
manual
data
collect
micropl
reader
tecan
cytotox
peptid
cell
measur
follow
instruct
manual
provid
cell
count
dojindo
kumamoto
kyushu
japan
briefli
seri
dilut
mix
target
cell
well
plate
incub
h
cultur
medium
replac
fresh
cell
medium
solut
incub
addit
h
c
absorb
nm
detect
readout
cell
viabil
anim
experiment
procedur
carri
accord
ethic
guidelin
approv
institut
laboratori
anim
care
use
committe
fudan
univers
approv
number
approv
date
septemb
antivir
activ
peptid
respiratori
tract
mice
intranas
administ
test
previous
describ
briefli
eightweekold
femal
balbc
mice
divid
two
group
mous
administ
pb
without
mg
intranas
rout
respect
h
mice
sacrif
euthanasia
upper
airway
lavag
pb
ml
pb
use
flush
lung
three
time
obtain
lower
lavag
fluid
plate
serial
dilut
detect
inhibitori
activ
smediat
cellcel
fusion
author
contribut
shibo
jiang
lu
lu
conceiv
design
experi
shuai
xia
establish
perform
smediat
cellcel
fusion
assay
wei
xu
establish
perform
pseudoviru
infect
assay
shuai
xia
wei
xu
perform
live
infect
assay
qian
wang
cong
wang
chen
hua
prepar
cell
virus
conduct
nativ
polyacrylamid
gel
electrophoresi
circular
dichroism
spectroscopi
cytotox
assay
respect
shuai
xia
wei
xu
weihua
li
analyz
data
shuai
xia
wei
xu
lu
lu
shibo
jiang
wrote
paper
